Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: A five-year follow-up

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 7, 2013, Pages 936-940

  Frega, A ^a   Sesti, F ^b   Sopracordevole, F ^c   Biamonti, A ^d   Scirpa, P ^e   Milazzo, G N ^a   Catalano, A ^a   Assorgi, C ^a   Lombardi, D ^a   Gentile, M ^a   Maniglio, P ^a   Ricciardi, E ^a   Cozza, G ^a   Marziani, R ^a   Moscarini, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d Cristo Re Hospital   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cold knife excision; Imiquimod; Overall complete response; Recurrence; VIN

Indexed keywords

IMIQUIMOD;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; COMPARATIVE STUDY; CREAM; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RECURRENCE RISK; RISK FACTOR; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; VULVA CARCINOMA; VULVA INTRAEPITHELIAL NEOPLASIA; VULVAR INTRAEPITHELIAL NEOPLASIA;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; OINTMENTS; VULVAR NEOPLASMS;

EID: 84878587137     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. SIDERI M, JONES RW, WILKINSON EJ, PRETI M, HELLER DS, SCURRY J, HAEFNER H, NEILL S. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD vulvar oncology subcommittee. J Reprod Med 2005; 50: 807-810.
2. LAI KW, MERCURIO MG. Medical and surgical approaches to vulvar intraepithelial neoplasia. Dermatol Ther 2010; 23: 477-484.
3. GASTRELL FH, MCCONNELL DT. Human papillomavirus and vulval intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2001; 15: 769-782.
4. HORDIN U, JUNGE J, POULSEN H, LUNDVALL F. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol 1995; 56: 276-279.
5. VAN BEURDEN M, TEN KATE FW, TJONG-A-HUNG SP, DE CRAEN AJ, VAN DER VANGE N, LAMMES FB, TER SCHEGGET J. Human papillomavirus DNA in multicentric vulvar intraepithelial neoplasia. Int J Gynecol Pathol 1998; 17: 12-16.
6. RH, KAUFMAN. Intraepithelial neoplasia of the vulva. Gynecol Oncol 1995; 56: 8-21.
7. VAN SETERS M, VAN BEURDEN M, DE CRAEN AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? a systematic review of 3322 published patients. Gynecol Oncol 2005; 97: 645-651.
8. JONES RW, ROWAN DM, STEWART AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005; 106: 1319-1326.
9. HEMMI H, KAISHO T, TAKEUCHI O, SATO S, SANJO H, HOSHINO K, HORIUCHI T, TOMIZAWA H, TAKEDA K, AKIRA S. Small antiviral compounds activate immune cells via TRL7 MyD88-dependent signaling pathway.Nat Immunol 2002; 3: 196-200.
10. FREGA A, SOPRACORDEVOLE F, ASSORGI C, LOMBARDI D, DE SANCTIS V, CATALANO A, MATTEUCCI E, MILAZZO GN, RICCIARDI E, MOSCARINI M. Vaginal intraepithelial neoplasia: a therapeutical dilemma. Anticancer Res 2013; 33: 29-38.
11. VAN SETERS M, VAN BEURDEN M, TEN KATE FJ, BECKMANN I, EWING PC, EIJKEMANS MJ, KAGIE MJ, MEIJER CJ, AARONSON NK, KLEINJAN A,HEIJMANS-ANTONISSEN C, ZIJLSTRA FJ, BURGER MP, HELMERHORST TJ. Treatment of vulvar intraepihtelial neoplasia with topical imiquimod. N Engl J Med 2008; 358: 1465-1473.
12. JUDSON PL, HABERMANN EB, BAXER NN, DURAM SB, VIRNIG BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006; 107: 1018-1022.
13. BRUCHIM I, GOTLIEB WH, MAHMUD S, TUNITSKY E, GRZYWACZ K, FERENCZY A. HPV-related vulvar intraepithelial neoplasia: outcome of different management modalities. Int J Gynaecol Obstet 2007; 99: 23-27.
14. LE T, HICKS W, MENARD C, HOPKINS L, FUNG KEE FUNG M. Prelimary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. Am J Obstet Gynecol 2006; 194: 377-380.
15. LE T, MENARD C, HICKS-BOUCHER M, HOPKINS L, WEBERPALS J, FUNG-KEE-FUNG M. Final results of a phase 2 study using continuous 5% imiquimod treatment of high grade vulva intraepithelial neoplasia. Gynecol Oncol 2007; 106: 579-584.
16. IAVAZZO C, PITSOUNI E, ATHANASIOU S, FALGAS ME. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet 2008; 101: 3-10.
17. WENDLING J, SAIAG P, BERVILLE-LEVY S, BOURGAULT-VILLADA I, CLERICI T, MOYAL-BARRACCO M. Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004; 140: 1220-1224.
18. ATHAVALE R, NAIK R, GODFREY KA, CROSS P, HATEM MH, DE BARROS LOPES A. Vulvar intraepithelial neoplasia- the need for auditable measures of management. Eur J Obstet Gynecol Reprod Biol 2008; 137: 97-102.
19. TERLOU A, VAN SETERS M, EWING PC, AARONSON N, GUNDY CM, HEIJMANS-ANTONISSEN C, QUINT WGV, BLOK LJ, VAN BEURDEN M, HELMEHORST TJM. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 2011;121: 157-162.
20. PEPAS L, KAUSHIK S, BRYANT A, NORDIN A, DICKINSON HO. Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2011; (4): CD007924.
21. WALLBILLICH JJ, RHODES HE, MILBOURNE AM, MUNSELL MF, FRUMOVITZ M, BROWN J, TRIMBLE CL, SCHMELER KM. Vulvar intraepithelial neoplasia (VIN 2/3): Comparing clinical outcomes and evaluating risk factors for recurrence. Gynecol Oncol 2012; 127: 312-315.
22. VAN SETERS M, FONS G, VAN BEURDEN M. Imiquimod in the treatment of multifocal intraepithelial neoplasia 2/3. results of a pilot study. J Reprod Med 2002; 47: 701-705.
23. COMMITTEE ON GYNECOLOGIC PRACTICE OF THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS AND THE AMERICAN SOCIETY FOR COLPOSCOPY AND CERVICAL PATHOLOGY. Management of vulvar intraepithelial neoplasia. J Low Genit Tract Dis 2012; 16: 1-3.
24. VON GRUENIGEN VE, GIBBONS HE, GIBBINS K, JENISON EL, HOPKINS MP. Surgical treatments for vulvar andvaginal dysplasia: a randomized controlled trial. Obstet Gynecol 2007; 109: 942-947.
25. KUPPERS V, STILLER M, SOMVILLE T, BENDER HG. Risk factors forrecurrent VIN. Role of multifocality and grade of disease. J Reprod Med 1997; 42: 140-144.
26. MUNOZ N, KJAER SK, SIGURDSSON K, IVERSEN OE, HERNANDEZ- AVILA M, WHEELER CM, PEREZ G, BROWN DR, KOUTSKY LA, TAY EH, GARCIA PJ, AULT KA, GARLAND SM, LEODOLTER S, OLSSON SE, TANG GW, FERRIS DG, PAAVONEN J, STEBEN M, BOSCH FX, DILLNER J, HUH WK, JOURA EA, KURMAN RJ, MAJEWSKI S, MYERS ER, VILLA LL, TADDEO FJ, ROBERTS C, TADESSE A, BRYAN JT, LUPINACCI LC, GIACOLETTI KE, SINGS HL, JAMES MK, HESLEY TM, BARR E, HAUPT RM. Impact of human papillomavirus (HPV) 6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-339.